3-[(2-Tert-butyl-1,1-dioxido-3-oxo-5-phenyl-2,3-dihydroisothiazol-4-yl)amino]propyl 4-methylbenzenesulfonate → HCID 11582415, compound
Reaction equation
[OH:1][C:2]1[CH:7]=[CH:6][N:5]=[CH:4][CH:3]=1.CC1C=CC(S(O[CH2:19][CH2:20][CH2:21][NH:22][C:23]2[C:24](=[O:40])[N:25]([C:36]([CH3:39])([CH3:38])[CH3:37])[S:26](=[O:35])(=[O:34])[C:27]=2[C:28]2[CH:33]=[CH:32][CH:31]=[CH:30][CH:29]=2)(=O)=O)=CC=1>CCOC(C)=O>[C:36]([N:25]1[C:24](=[O:40])[C:23]([NH:22][CH2:21][CH2:20][CH2:19][O:1][C:2]2[CH:7]=[CH:6][N:5]=[CH:4][CH:3]=2)=[C:27]([C:28]2[CH:29]=[CH:30][CH:31]=[CH:32][CH:33]=2)[S:26]1(=[O:34])=[O:35])([CH3:37])([CH3:38])[CH3:39]Participants
Procedure
The title compound was prepared as described for Example 12 from 4-hydroxypyridine and 3-[(2-tert-butyl-1,1-dioxido-3-oxo-5-phenyl-2,3-dihydroisothiazol-4-yl)amino]propyl 4-methylbenzenesulfonate with a reaction time of 15 mins. EtOAc was added to the reaction mixture and the mixture was washed with water, brine and evaporated. The residue was purified twice by silica gel column chromatography (Horizons Biotage) using 50-80% EtOAc in hexane then 50% EtOAc in DCM as eluent to give the title compound (0.035 g, 35%). 1H NMR (500 MHz CDCl3): δ 8.44 (d, 2H), 7.54-7.48 (m, 2H), 7.48-7.41 (m, 3H), 6.75 (d, 2H), 5.64 (t, 1H), 3.91 (t, 2H), 3.114-3.08 (m, 2H), 1.90-1.82 (m, 2H), 1.74 (s, 9H); 13C NMR (125 MHz CDCl3): δ 164.5, 159.8, 151.4, 135.2, 131.8, 129.9, 128.9, 125.2, 110.3, 107.6, 65.7, 61.8, 41.9, 28.8, 27.9; Mass Spectrum: M+H+ 416.
Workup
- customThe title compound was prepared
- washthe mixture was washed with water, brine
- customevaporated
- customThe residue was purified twice by silica gel column chromatography (Horizons Biotage)
Sources & evidence
- ORD record
- ord-c09ea1621827465fb4cf9cc6f16bde1e
- Source dataset
- uspto-grants-2011_06
- Patent number
- US07960380B2
Reaction notes
Loading…